4-HO-MPT
Pharmaceutical compound
From Wikipedia, the free encyclopedia
4-HO-MPT, also known as 4-hydroxy-N-methyl-N-propyltryptamine or as meprocin, is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families.[1][2] It is a higher homologue of psilocin (4-HO-DMT) as well as the 4-hydroxyl analogue of N-methyl-N-propyltryptamine (MPT).[1][2] The drug is taken orally.[1][2]
- None
 | |
 | |
| Clinical data | |
|---|---|
| Other names | 4-OH-MPT; 4-Hydroxy-N-methyl-N-propyltryptamine; Meprocin |
| Routes of administration | Oral[1][2] |
| Drug class | Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H20N2O |
| Molar mass | 232.327 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
It acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor.[3][4] The drug produces psychedelic-like effects in animals.[2][3]
4-HO-MPT was first described in the scientific literature by 1981.[5] It was encountered as a novel designer drug by 2021.[6]
Use and effects
The dose and duration of 4-HO-MPT are listed as "unknown" in Alexander Shulgin's book TiHKAL (Tryptamines I Have Known and Loved).[1] In more recent publications, the dose has been reported to be 20 to 30 mg orally, with a mean dose of 25 mg.[2] In a single trial of 8 mg 4-HO-MPT hydrochloride orally from TiHKAL, it was described as producing visual distortion, vertigo, and slight insomnia.[1]
Interactions
Pharmacology
Pharmacodynamics
| Target | Affinity (Ki, nM) |
|---|---|
| 5-HT1A | 106–910 (Ki) 490 (EC50) 90% (Emax) |
| 5-HT1B | 224 |
| 5-HT1D | 170 |
| 5-HT1E | 246 |
| 5-HT2A | 71–114 (Ki) 3.8–64a (EC50) 53%a–98% (Emax) |
| 5-HT2B | 8 (Ki) 3.4 (EC50) 58% (Emax) |
| 5-HT2C | 150–203 (Ki) 46–66a (EC50) 83–100%a (Emax) |
| 5-HT5A | 664 |
| 5-HT6 | 48 |
| 5-HT7 | 99 |
| α2A | 3,625 |
| α2B | 1,844 |
| α2C | IA |
| D2 | IA |
| D3 | 921 |
| D4, D5 | IA |
| H1 | 92 |
| H2 | IA |
| M4 | IA |
| σ1 | 891 |
| σ2 | 1,166 |
| KOR | IA |
| NR2B | 3,658 |
| SERT | 910–1,180 (Ki) 575 (IC50) |
| DAT | IA |
| Notes: The smaller the value, the more avidly the drug binds to the site. Footnotes: a = Stimulation of IP1 formation. Sources: [3][4][7] | |
4-HO-MPT acts as a potent agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors.[3][4] It is a partial or full agonist of the serotonin 5-HT2A receptor, a moderate-efficacy partial agonist of the serotonin 5-HT2B receptor, and a high-efficacy partial agonist of the serotonin 5-HT2C receptor.[3][8] The drug has more than an order of magnitude higher potency as an agonist of the serotonin 5-HT2A and 5-HT2B receptors than as an agonist of the serotonin 5-HT2C receptor.[3] It also interacts with other serotonin receptors such as 5-HT6 and 5-HT7 receptors with high affinity and non-serotonergic targets.[4] Additionally it inhibits serotonin transporter.[9]
4-HO-MPT produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[2][3]
Chemistry
History
4-HO-MPT was first described in the scientific literature by David Repke and colleagues in 1981.[5] Subsequently, its effects in humans were described by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved).[1] The drug was encountered as a novel designer drug by 2021.[6]
Society and culture
Legal status
International
4-HO-MPT is not scheduled by the United Nations' Convention on Psychotropic Substances.[10]
Canada
4-HO-MPT is not an explicitly nor implicitly controlled substance in Canada as of 2025.[11]
United States
4-HO-MPT is not scheduled at the federal level in the United States,[12] but it is possible that 4-HO-MPT could legally be considered an analog of psilocin, in which case, sales or possession with intent for human consumption could potentially be prosecuted under the Federal Analogue Act.[13]